Enterococcal endocarditis: Can we win the war?

Current Infectious Disease Reports

Volumn 14, Issue 4, 2012, Pages 339-349

  Munita, Jose M ^b,d   Arias, Cesar A ^a,b,c   Murray, Barbara E ^a,b  

^a Center for the Study of Emerging and Reemerging Pathogens   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSIDAD EL BOSQUE   (Colombia)

^d UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

Enterococcus; Infective endocarditis; Multi drug resistant enterococci; Therapy; Vancomycin resistance

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; CEFOTAXIME; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; GLYCYLCYCLINE DERIVATIVE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; LIPOPEPTIDE; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; RIFAMPICIN; STREPTOGRAMIN DERIVATIVE; STREPTOMYCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL LOAD; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HIGH RISK POPULATION; HUMAN; INFECTION RISK; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; MYALGIA; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHLEBITIS; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 84865627160     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0270-8     Document Type: Article

References (115)

1. MacCallum WG, Hastings TW. A case of acute endocarditis caused by Micrococcus zymogenes (nov. spec.), with a description of the microorganism. J Exp Med. 1899;4:521-34.
2. Galloway-Peña J, Roh JH, Latorre M, Qin X, Murray BE. Genomic and SNP analyses demonstrate a distant separation of the hospital and community-Associated clades of Enterococcus faecium. PLoS One. 2012;7(1):e30187. This paper compares 100 core genes from the available E. faecium genomes and shows that community-Associated and hospital-Associated strains belong to two ancestral clades.
3. Palmer KL, Godfrey P, Griggs A, Kos VN, Zucker J, Desjardins C, Cerqueira G, Gevers D, Walker S, Wortman J, Feldgarden M, Haas B, Birren B, Gilmore MS. Comparative Genomics of Enterococci: Variation in Enterococcus faecalis, Clade Structure in E. faecium, and Defining Characteristics of E. gallinarum and E. casseliflavus. MBio. 2012;3(1):e00318-11.
4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12.
5. Arias CA, Murray BE. The rise of the Enterococcus: Aeyond vancomycin resistance. Nat Rev Microbiol. 2012;10(4):266-78.
6. Moreillon P, Que YA. Infective endocarditis. Lancet. 2004;363 (9403):139-49. (Pubitemid 38068333)
7. Olmsted SB, Kao SM, van Putte LJ, Gallo JC, Dunny GM. Role of the pheromone-inducible surface protein Asc10 in mating aggregate formation and conjugal transfer of the Enterococcus faecalis plasmid pCF10. J Bacteriol. 1991;173 (23):7665-72.
8. Waters CM, Hirt H, McCormick JK, Schlievert PM, Wells CL, Dunny GM. An amino-Terminal domain of Enterococcus faecalis aggregation substance is required for aggregation, bacterial internalization by epithelial cells and binding to lipoteichoic acid. Mol Microbiol. 2004;52(4):1159-71. (Pubitemid 38916181)
9. Chuang-Smith ON, Wells CL, Henry-Stanley MJ, Dunny GM. Acceleration of Enterococcus faecalis biofilm formation by aggregation substance expression in an ex vivo model of cardiac valve colonization. PLoS One. 2010;5(12):e15798.
10. Schlievert PM, Gahr PJ, Assimacopoulos AP, Dinges MM, Stoehr JA, Harmala JW, et al. Aggregation and binding substances enhance pathogenicity in rabbit models of Enterococcus faecalis endocarditis. Infect Immun. 1998;66(1):218-23. (Pubitemid 28018823)
11. Schlievert PM, Chuang-Smith ON, Peterson ML, Cook LC, Dunny GM. Enterococcus faecalis endocarditis severity in rabbits is reduced by IgG Fabs interfering with aggregation substance. PLoS One. 2010;5(10):e13194.
12. Nallapareddy SR, Singh KV, Murray BE. Contribution of the collagen adhesin Acm to pathogenesis of Enterococcus faecium in experimental endocarditis. Infect Immun. 2008;76 (9):4120-8.
13. Singh KV, Nallapareddy SR, Sillanpää J, Murray BE. Importance of the collagen adhesin ace in pathogenesis and protection against Enterococcus faecalis experimental endocarditis. PLoS Pathog. 2010;6(1):e1000716.
14. Heikens E, Bonten MJ, Willems RJ. Enterococcal surface protein Esp is important for biofilm formation of Enterococcus faecium E1162. J Bacteriol. 2007;189:8233-40. (Pubitemid 350178935)
15. Heikens E, Singh KV, Jacques-Palaz KD, van Luit Asbroek M, Oostdijk EA, Bonten MJ, et al. Contribution of the enterococcal surface protein Esp to pathogenesis of Enterococcus faecium endocarditis. Microbes Infect. 2011;13(14-15):1185-90.
16. Kemp KD, Singh KV, Nallapareddy SR, Murray BE. Relative contributions of Enterococcus faecalis OG1RF sortase-encoding genes, srtA and bps (srtC), to biofilm formation and a murine model of urinary tract infection. Infect Immun. 2007;75(11):5399-404. (Pubitemid 350033628)
17. Nallapareddy SR, Singh KV, Sillanpää J, Zhao M, Murray BE. Relative contributions of Ebp Pili and the collagen adhesin ace to host extracellular matrix protein adherence and experimental urinary tract infection by Enterococcus faecalis OG1RF. Infect Immun. 2011;79(7):2901-10.
18. Nallapareddy SR, Singh KV, Sillanpää J, Garsin DA, Höök M, Erlandsen SL, et al. Endocarditis and biofilm-Associated pili of Enterococcus faecalis. J Cl in Invest. 2006;116(10):2799-807. (Pubitemid 44511643)
19. Sillanpää J, Nallapareddy SR, Singh KV, Prakash VP, Fothergill T, Ton-That H, et al. Characterizationof the ebp(fm) pilusencoding operon of Enterococcus faecium and its role in biofilm formation and virulence in a murine model of urinary tract infection. Virulence. 2010;1(4):236-46.
20. Chow JW, Thal LA, Perri MB, Vazquez JA, Donabedian SM, Clewell DB, et al. Plasmid-Associated hemolysin and aggregation substance production contribute to virulence in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1993;37(11):2474-7. (Pubitemid 23324477)
21. ThomasVC, HiromasaY, Harms N, Thurlow L, Tomich J, Hancock LE. A fratricidal mechanism is responsible for eDNA release and contributes to biofilm development of Enterococcus faecalis. Mol Microbiol. 2009;72(4):1022-36.
22. Singh KV, Nallapareddy SR, Nannini EC, Murray BE. Fsr independent production of protease(s) may explain the lack of attenuation of an Enterococcus faecalis fsr mutant versus a gelE-sprE mutant in induction of endocarditis. Infect Immun. 2005;73 (8):4888-94. (Pubitemid 41105645)
23. Thurlow LR, Thomas VC, Narayanan S, Olson S, Fleming SD, Hancock LE. Gelatinase contributes to the pathogenesis of endocarditis caused by Enterococcus faecalis. Infect Immun. 2010;78 (11):4936-43.
24. Nannini EC, Teng F, Singh KV, Murray BE. Decreased virulence of a gls24 mutant of Enterococcus faecalis OG1RF in an experimental endocarditis model. Infect Immun. 2005;73(11):7772-4. (Pubitemid 41587685)
25. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler Jr. VG, Bayer AS, et al. International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: The International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169(5):463-73.
26. Bouza E, Menasalvas A, Muñoz P, Vasallo FJ, del Mar Moreno M, García Fernández MA. Infective endocarditis-A prospective study at the end of the twentieth century: New predisposing conditions, new etiologic agents, and still a high mortality. Medicine (Baltimore). 2001;80(5):298-307. (Pubitemid 32879291)
27. Hill EE, Herijgers P, Claus P, Vanderschueren S, Herregods MC, Peetermans WE. Infective endocarditis: Changing epidemiology and predictors of 6-month mortality: A prospective cohort study. Eur Heart J. 2007;28(2):196-203.
28. Alonso-Valle H, Fariñas-Alvarez C, Bernal-Marco JM, García-Palomo JD, Gutiérrez-Díez F, Martín Durán R, de Berrazueta JR, González-Macías J, Revuelta-Soba JM, Fariñas MC. The changing face of prosthetic valve endocarditis at a tertiary-care hospital: 1986-2005. Rev Esp Cardiol. 2010;63(1):28-35.
29. Fernández-Hidalgo N, Almirante B, Tornos P, Pigrau C, Sambola A, Igual A, et al. Contemporary epidemiology and prognosis of health care-Associated infective endocarditis. Clin Infect Dis. 2008;47(10):1287-97.
30. Benito N, Miró JM, de Lazzari E, Cabell CH, del Río A, Altclas J, et al. Health care-Associated native valve endocarditis: Importance of non-nosocomial acquisition. Ann Intern Med. 2009;150 (9):586-94.
31. Sy RW, Kritharides L. Health care exposure and age in infective endocarditis: results of a contemporary populationbased profile of 1536 patients in Australia. Eur Heart J. 2010;31(15):1890-7.
32. Hidron AI, et al. NHSN annual update: Antimicrobial-resistant pathogens associated with healthcare-Associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29:996-1011.
33. Maki DG, Agger WA. Enterococcal bacteremia: Clinical features, the risk of endocarditis, and management. Medicine (Baltimore). 1988;67(4):248-69.
34. Fernández-Guerrero ML, Herrero L, Bellver M, Gadea I, Roblas RF, de Górgolas M. Nosocomial enterococcal endocarditis: A serious hazard for hospitalized patients with enterococcal bacteraemia. J Intern Med. 2002;252(6):510-5. (Pubitemid 35454327)
35. Megran DW. Enterococcal endocarditis. Clin Infect Dis. 1992;15 (1):63-71.
36. Anderson DJ, Murdoch DR, Sexton DJ, Reller LB, Stout JE, Cabell CH, et al. Risk factors for infective endocarditis in patients with enterococcal bacteremia: A case-control study. Infection. 2004;32(2):72-7. (Pubitemid 38457099)
37. Fernández Guerrero ML, Goyenechea A, Verdejo C, Roblas RF, de Górgolas M. Enterococcal endocarditis on native and prosthetic valves: A review of clinical and prognostic factors with emphasis on hospital-Acquired infections as a major determinant of outcome. Medicine (Baltimore). 2007;86(6):363-77. (Pubitemid 351326059)
38. Rice LB, Calderwood SB, Eliopoulos GM, Farber BF, Karchmer AW. Enterococcal endocarditis: A comparison of prosthetic and native valve disease. Rev Infect Dis. 1991;13(1):1-7.
39. Martínez-Odriozola P, Muñoz-Sánchez J, Gutiérrez-Macías A, Arriola-Martínez P, Montero-Aparicio E, Ezpeleta Baquedano C, et al. [An analysis of 182 enterococcal bloodstream infections: Epidemiology, microbiology, and outcome]. Enferm Infecc Microbiol Clin. 2007;25(8):503-7. (Pubitemid 47535956)
40. Poh CH, Oh HM, Tan AL. Epidemiology and clinical outcome of enterococcal bacteraemia in an acute care hospital. J Infect. 2006;52(5):383-6.
41. McDonald JR, Olaison L, Anderson DJ, Hoen B, Miro JM, Eykyn S, et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am J Med. 2005;118(7):759-66. (Pubitemid 40897662)
42. Vijayvargiya R, Veis JH. Antibiotic-resistant endocarditis in a hemodialysis patient. J Am Soc Nephrol. 1996;7(4):536-42. (Pubitemid 126427118)
43. Bishara J, Sagie A, Samra Z, Pitlik S. Polymicrobial endocarditis caused by methicillin-resistant Staphylococcus aureus and glycopeptide-resistant enterococci. Eur J Clin Microbiol Infect Dis. 1999;18(9):674-5. (Pubitemid 29531249)
44. Stevens MP, Edmond MB. Endocarditis due to vancomycinresistant enterococci: Case report and review of the literature. Clin Infect Dis. 2005;41(8):1134-42. (Pubitemid 41429476)
45. Forrest GN, Arnold RS, Gammie JS, Gilliam BL. Single center experience of a vancomycin resistant enterococcal endocarditis cohort. J Infect. 2011;63(6):420-8.
46. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev. 1990;3:46-65. (Pubitemid 20078774)
47. Robbins WC, Tompsett R. Treatment of enterococcal endocarditis and bacteremia; results of combined therapy with penicillin and streptomycin. Am J Med. 1951;10(3):278-99.
48. Jawetz E, Gunnison JB, Coleman VR. The combined action of penicillin with streptomycin or chloromycetin on enterococci in vitro. Science. 1950;111(2880):254-6.
49. Wright AJ, Wilson WR, Matsumoto JY, Washington 2nd JA, Geraci JE. Influence of gentamicin dose size on the efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococcal endocarditis. Antimicrob Agents Chemother. 1982;22(6):972-5. (Pubitemid 13190645)
50. Wilson WR, Wilkowske CJ, Wright AJ, Sande MA, Geraci JE. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med. 1984;100(6):816-23. (Pubitemid 14121590)
51. Serra P, Brandimarte C, Martino P, Carlone S, Giunchi G. Synergistic treatment of enterococcal endocarditis: In vitro and in vivo studies. Arch Intern Med. 1977;137(11):1562-7. (Pubitemid 9016452)
52. Baddour LM, Wilson WR, Bayer AS, Fowler Jr. VG, Bolger AF, Levison ME, et al. Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America. Circulation. 2005;111(23):e394-434.
53. Murray BE. Beta-lactamase-producing enterococci. Antimicrob Agents Chemother. 1992;36(11):2355-9.
54. Eliopoulos GM, Farber BF, Murray BE, Wennersten C, Moellering Jr. RC. Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother. 1984;25 (3):398-9. (Pubitemid 14166506)
55. Mainardi JL, Gutmann L, Acar JF, Goldstein FW. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother. 1995;39(9):1984-7.
56. Gavaldà J, Torres C, Tenorio C, López P, Zaragoza M, Capdevila JA, et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother. 1999;43(3):639-46. (Pubitemid 29109532)
57. Gavaldà J, Len O, Miró JM, Muñoz P, Montejo M, Alarcón A, et al. Brief communication: Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med. 2007;146 (8):574-9. This multicenter, non-randomized, open-label study evaluates the combination of ceftriaxone plus ampicillin in the treatment of E. faecalis endocarditis, particularly important in the setting of high-level resistance to aminoglycosides. (Pubitemid 351650538)
58. Antony SJ, Ladner J, Stratton CW, Raudales F, Dummer SJ. High-level aminoglycoside-resistant enterococcus causing endocarditis successfully treated with a combination of ampicillin, imipenem and vancomycin. Scand J Infect Dis. 1997;29 (6):628-30.
59. Tripodi MF, Locatelli A, Adinolfi LE, Andreana A, Utili R. Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci. Eur J Clin Microbiol Infect Dis. 1998;17(10): 734-6. (Pubitemid 29218999)
60. Rice LB, Bellais S, Carias LL, Hutton-Thomas R, Bonomo RA, Caspers P, et al. Impact of specific pbp5 mutations on expression of beta-lactam resistance in Enterococcus faecium. Antimicrob Agents Chemother. 2004;48(8):3028-32. (Pubitemid 38989171)
61. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med. 2000;10:710-21. (Pubitemid 30131425)
62. Galloway-Peña JR, Nallapareddy SR, Arias CA, Eliopoulos GM, Murray BE. Analysis of clonality and antibiotic resistance among early clinical isolates of Enterococcus faecium in the United States. J Infect Dis. 2009;200(10):1566-73.
63. Bryson HM, Spencer CM. Quinupristin-dalfopristin. Drugs. 1996;52(3):406-15.
64. Linden PK, Moellering Jr. RC, Wood CA, Rehm SJ, Flaherty J, Bompart F, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis. 2001;33(11):1816-23. (Pubitemid 33105119)
65. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother. 1999;44(2):251-61. (Pubitemid 29389289)
66. Linden PK. Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med. 2007;28(6):632-45.
67. Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis. 2001;32:e83-6.
68. Bethea JA, Walko CM. Treatment of vancomycinresistant enterococcus with quinupristin/dalfopristin. Ann Pharmacother. 2004;38(6):989-91.
69. Arias CA, Murray BE. Emergence and management of drug resistant enterococcal infections. Expert Rev Anti Infect Ther. 2008;6(5):637-55. Extensive review of the treatment options for enterococcal infections, with particular emphasis in multi-drug resistant isolates.
70. Fantin B, Leclercq R, Garry L, Carbon C. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-Type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob Agents Chemother. 1997;41(5):931-5. (Pubitemid 27194163)
71. Pérez Salmerón J, Martínez García F, Roldán Conesa D, Lorente Salinas I, López Fornás F, Ruiz Gómez J, et al. Comparative study of treatment with quinupristin dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium. Rev Esp Quimioter. 2006;19(3):258-66. (Pubitemid 44727357)
72. Matsumura S, Simor AE. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: A synergistic drug combination. Clin Infect Dis. 1998;27(6):1554-6. (Pubitemid 29242454)
73. Bethea JA, Walko CM, Targos PA. Treatment of vancomycinresistant enterococcus with quinupristin/dalfopristin and highdose ampicillin. Ann Pharmacother. 2004;38(6):989-91. (Pubitemid 38657740)
74. Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: Cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. South Med J. 2003;96(8):818-20. (Pubitemid 38281699)
75. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolidresistant, vancomycin-resistant Enterococcus faecium. N Engl J Med. 2002;346(11):867-9. (Pubitemid 34984671)
76. Arias CA, Vallejo M, Reyes J, Panesso D, Moreno J, Castañeda E, et al. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23 S rRNA methyltransferase. J Clin Microbiol. 2008;46(3):892-6. (Pubitemid 351379975)
77. Diaz L, Kiratisin P, Mendes R, Panesso D, Singh K, Arias CA. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. April 01 2012. Accepted for publication in AAC
78. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis. 2003;36 (2):159-68. (Pubitemid 36143412)
79. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: A systematic review of the published evidence. J Antimicrob Chemother. 2006;58 (2):273-80. (Pubitemid 44313381)
80. Hamza N, Ortiz J, Bonomo RA. Isolated pulmonic valve infective endocarditis: A persistent challenge. Infection. 2004;32(3):170-5. (Pubitemid 38757023)
81. Zimmer SM, Caliendo AM, Thigpen MC, Somani J. Failure of linezolid treatment for enterococcal endocarditis. Clin Infect Dis. 2003;37(3):e29-30.
82. Rao N, White GJ. Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin Infect Dis. 2002;35(7):902-4.
83. Wareham DW, Abbas H, Karcher AM, Das SS. Treatment of prosthetic valve infective endocarditis due to multi resistant Gram-positive bacteria with linezolid. J Infect. 2006;52 (4):300-4.
84. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis. 2001;32 (9):1373-5. (Pubitemid 32405913)
85. Ang JY, Lua JL, Turner DR, Asmar BI. Vancomycin resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid. Pediatr Infect Dis J. 2003;22 (12):1101-3. (Pubitemid 37543414)
86. Archuleta S, Murphy B, Keller MJ. Successful treatment of vancomycin-resistant Enterococcus faecium endocarditis with linezolid in a renal transplant recipient with human immunodeficiency virus infection. Transpl Infect Dis. 2004;6 (3):117-9. (Pubitemid 40013051)
87. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis. 2000;30(1):146-51. (Pubitemid 30067072)
88. Tsigrelis C, Singh KV, Coutinho TD, Murray BE, Baddour LM. Vancomycin-resistant Enterococcus faecalis endocarditis: Linezolid failure and strain characterization of virulence factors. J Clin Microbiol. 2007;45(2):631-5.
89. Berdal JE, Eskesen A. Short-Term success, but long term treatment failure with linezolid for enterococcal endocarditis. Scand J Infect Dis. 2008;40(9):765-6.
90. Schwartz BS, Ngo PD, Guglielmo BJ. Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: Impact of protein binding? Ann Pharmacother. 2008;42(2):289-90. (Pubitemid 351238581)
91. Carpenter CF, Chambers HF. Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38(7):994-1000.
92. Kamboj M, Cohen N, Gilhuley K, Babady NE, Seo SK, Sepkowitz KA. Emergence of daptomycin-resistant VRE: Experience of a single institution. Infect Control Hosp Epidemiol. 2011;32(4):391-4.
93. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: An emerging challenge for clinicians. Clin Infect Dis. 2011;52(2):228-34.
94. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med. 2011;365(10):892-900. In this paper novel genes involved in in vivo enterococcal daptomycin nonsusceptibility are identified.
95. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother. 2011;55(7):3345-56.
96. Caron F, Kitzis MD, Gutmann L, Cremieux AC, Maziere B, Vallois JM, et al. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother. 1992;36 (12):2611-6.
97. Cha R, Rybak MJ. Daptomycin against multiple drug resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis. 2003;47(3):539-46. (Pubitemid 37338519)
98. Vouillamoz J, Moreillon P, Giddey M, Entenza JM. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother. 2006;58(6):1208-14. (Pubitemid 44884140)
99. Ramos MC, Grayson ML, Eliopoulos GM, Bayer AS. Comparison of daptomycin, vancomycin, and ampicillin gentamicin for treatment of experimental endocarditis caused by penicillinresistant enterococci. Antimicrob Agents Chemother. 1992;36 (9):1864-9.
100. Cervera C, Castañeda X, Pericas JM, Del Río A, de la Maria CG, Mestres C, et al. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci. Int J Antimicrob Agents. 2011;38(5):365-70.
101. Jenkins I. Linezolid-And vancomycin-resistant Enterococcus faecium endocarditis: Successful treatment with tigecycline and daptomycin. J Hosp Med. 2007;2(5):343-4. (Pubitemid 350020012)
102. Polidori M, Nuccorini A, Tascini C, Gemignani G, Iapoce R, Leonildi A, et al. Vancomycin-resistant Enterococcus faecium (VRE) bacteremia in infective endocarditis successfully treated with combination daptomycin and tigecycline. J Chemother. 2011;23(4):240-1.
103. Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother. 2009;43(12):2108-12.
104. Arias CA, Torres HA, Singh KV, Panesso D,Moore J,Wanger A, et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis. 2007;45(10):1343-6. (Pubitemid 351411911)
105. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, et al. Ampicillin enhances daptomycin-And cationic host defense peptide mediated killing of ampicillin-And vancomycin resistant Enterococcus faecium. Antimicrob Agents Chemother. 2012;56(2):838-44. The authors report in vitro and in vivo synergism between daptomycin and ampicillin for the treatment of a patient with endocarditis due to a VRE faecium, despite the fact that the isolate had high-level of resistance to ampicillin.
106. Beneri CA, Nicolau DP, Seiden HS, Rubin LG. Successful treatment of a neonate with persistent vancomycin resistant enterococcal bacteremia with a daptomycin-containing regimen. Infect Drug Resist. 2008;1:9-11.
107. Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 1991;35(12):2505-8.
108. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. Evaluation of Standard and High-Dose Daptomycin versus Linezolid against Vancomycin-Resistant Enterococcus in a Simulated Endocardial Vegetations (SEV) in vitro Pharmacokinetic/Pharmacodynamic model. Antimicrob Agents Chemother. 2012 Apr 2. [Epub ahead of print] PubMed PMID: 22470111.
109. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: A worldwide sample of 6737 clinical Gram positive organisms. J Antimicrob Chemother. 2004;53(4):669-74. (Pubitemid 38499788)
110. Rose WE, Rybak MJ. Tigecycline: First of a new class of antimicrobial agents. Pharmacotherapy. 2006;26(8):1099-110. (Pubitemid 44167819)
111. Werner G, Gfrörer S, Fleige C, Witte W, Klare I. Tigecyclineresistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother. 2008;61(5):1182-3. (Pubitemid 351524469)
112. Freitas AR, Novais C, Correia R, Monteiro M, Coque TM, Peixe L. Non-susceptibility to tigecycline in enterococci from hospitalised patients, food products and community sources. Int J Antimicrob Agents. 2011;38(2):174-6.
113. Murphy TM, Deitz JM, Petersen PJ, Mikels SM, Weiss WJ. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother. 2000;44(11):3022-7.
114. Lefort A, Lafaurie M, Massias L, Petegnief Y, Saleh-Mghir A, Muller-Serieys C, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 2003;47(1):216-22. (Pubitemid 36070367)
115. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: A review of in vitro, animal and case report studies. Int J Antimicrob Agents. 2009;34(1):8.e1-9.